Comparison of psoriasis guidelines for use of apremilast in the United States and Europe : a critical appraisal and comprehensive review
PURPOSE: This review article serves to compare global dermatologic organizations and the available clinical practice guidelines for the use of apremilast in the treatment of psoriasis.
MATERIALS AND METHODS: Guidelines from the American Academy of Dermatology (AAD), the National Psoriasis Foundation (NPF), the European S3, the National Institute for Health and Care Excellence (NICE), the French Society of Dermatology (SFD), the Swiss S1, and Italy were reviewed and compared.
RESULTS: Of the American and European guidelines available for use of apremilast, several organizations are in agreement regarding the dosage of apremilast, but there are significant disagreements concerning matters such as medication indication, pretreatment laboratory testing, and contraindications to therapy.
CONCLUSION: Apremilast is an effective and well-tolerated treatment option for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients, especially those with contraindications to other systemic therapies such as biologics. Consideration should be given to the evidence-based recommendations of global dermatology organizations to help guide therapeutic decisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 33(2022), 1 vom: 02. Feb., Seite 94-99 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghamrawi, Rima I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z8R6ORS6L |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 01.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2020.1770176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310021669 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310021669 | ||
| 003 | DE-627 | ||
| 005 | 20231225135206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2020.1770176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310021669 | ||
| 035 | |a (NLM)32419531 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghamrawi, Rima I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of psoriasis guidelines for use of apremilast in the United States and Europe |b a critical appraisal and comprehensive review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 01.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: This review article serves to compare global dermatologic organizations and the available clinical practice guidelines for the use of apremilast in the treatment of psoriasis | ||
| 520 | |a MATERIALS AND METHODS: Guidelines from the American Academy of Dermatology (AAD), the National Psoriasis Foundation (NPF), the European S3, the National Institute for Health and Care Excellence (NICE), the French Society of Dermatology (SFD), the Swiss S1, and Italy were reviewed and compared | ||
| 520 | |a RESULTS: Of the American and European guidelines available for use of apremilast, several organizations are in agreement regarding the dosage of apremilast, but there are significant disagreements concerning matters such as medication indication, pretreatment laboratory testing, and contraindications to therapy | ||
| 520 | |a CONCLUSION: Apremilast is an effective and well-tolerated treatment option for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients, especially those with contraindications to other systemic therapies such as biologics. Consideration should be given to the evidence-based recommendations of global dermatology organizations to help guide therapeutic decisions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Apremilast | |
| 650 | 4 | |a clinical practice guidelines | |
| 650 | 4 | |a phosphodiesterase 4 inhibitor | |
| 650 | 4 | |a psoriasis | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a apremilast |2 NLM | |
| 650 | 7 | |a UP7QBP99PN |2 NLM | |
| 700 | 1 | |a Ghiam, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jashin J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 33(2022), 1 vom: 02. Feb., Seite 94-99 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:1 |g day:02 |g month:02 |g pages:94-99 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2020.1770176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 1 |b 02 |c 02 |h 94-99 | ||